JPRN-UMIN000015203
尚未招募
未知
Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension. - Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension.
Takeda Hospital Medical Examination Center0 个研究点目标入组 30 人2014年9月18日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- type 2 diabetes
- 发起方
- Takeda Hospital Medical Examination Center
- 入组人数
- 30
- 状态
- 尚未招募
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •1\) Patients who are Type I or Secondary diabetic mellitus 2\) Patients who are treating with Insulin theraphy at the time of study initiation 3\) Patients who are severe infectious disease, perioperative, and severe trauma 4\)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant 5\)Patients with myocardial infarction, angina pectoris, cerebral stroke, or cerebral infarction before 3 month 6\) patients with Arrhythmia,atrial fibrillation 7\) Patients with a history of hypersensitivity to investigational drugs 8\) Patients with cancer 9\) Patients who receive steroid therapy with inflammatory affection 10\) Patients whom doctor judges as ineligible to this study
结局指标
主要结局
未指定
相似试验
已完成
3 期
DECLARE-TIMI58JPRN-jRCT2080222423AstraZeneca KK17,150
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.EUCTR2013-000239-28-NLAstraZeneca AB17,150
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 19.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 19.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-000239-28-SEAstraZeneca AB17,160
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 19.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-000239-28-SKAstraZeneca AB17,150
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 20.0 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent System Organ Class: 100000072461Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-000239-28-CZAstraZeneca AB17,160